Regeneron Pharmaceuticals, Inc. is best known for Eylea. The drug, which is used to treat three eye diseases, generated $3.1 billion in 2015 for Regeneron and nearly $950 million for the biotech’s partner, Bayer.
Many observers expected that Regeneron’s partnership with Sanofi to develop and market PCSK9 inhibitor Praluent could lead to the next blockbuster alongside Eylea. However, sales for the cholesterol drug have been disappointing so far.
Another drug in the pipeline for Regeneron and Sanofi could be better positioned to meet expectations and top that magical billion-dollar sales mark. Here’s why Dupixent could be Regeneron’s next blockbuster.
